Figure 1
Figure 1. Risk of CNS relapse in dual expresser MYC+BCL2+. Cumulative frequency of CNS relapse in dual expresser (MYC+BCL2+) vs non-dual expresser (non-MYC+BCL2+) (A) in DLBCL, (B) in ABC DLBCL by Lymph2Cx, (C) in GCB DLBCL by Lymph2Cx, (D) in high-risk CNS-IPI (4 or more factors) DLBCL, and (E) in intermediate risk CNS-IPI (2 to 3 factors) DLBCL.

Risk of CNS relapse in dual expresser MYC+BCL2+. Cumulative frequency of CNS relapse in dual expresser (MYC+BCL2+) vs non-dual expresser (non-MYC+BCL2+) (A) in DLBCL, (B) in ABC DLBCL by Lymph2Cx, (C) in GCB DLBCL by Lymph2Cx, (D) in high-risk CNS-IPI (4 or more factors) DLBCL, and (E) in intermediate risk CNS-IPI (2 to 3 factors) DLBCL.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal